✦ LIBER ✦

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

✍ Scribed by Rong Wang; Cary P. Gross; Stephanie Halene; Xiaomei Ma

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 240 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.02.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemtuzumab, fludarabine, cytarabine, and

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

✍ Apostolia Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (aml). the fludarabine and cytarabine (ara-c) regimen is active in these patients. resistance to gemtuzumab is associated with blast multidrug resistance (mdr). the objectives of th

Evaluation of the prognostic significanc

Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes

✍ Friedrich Wimazal; Ulrich Germing; Michael Kundi; Thomas Noesslinger; Sabine Blu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 365 KB 👁 1 views

## Abstract ## BACKGROUND: Lineage involvement and maturation arrest are considered to have prognostic significance in patients with myelodysplastic syndromes (MDS). However, although the prognostic value of neutropenia, thrombocytopenia, and monocytosis have been documented, little is known about

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

Distress, psychiatric syndromes, and imp

Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer

✍ Mark T. Hegel; Caroline P. Moore; E. Dale Collins; Stephen Kearing; Karen L. Gil 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

Evaluation of the 1987 revised criteria

Evaluation of the 1987 revised criteria for rheumatoid arthritis in a cohort of newly diagnosed female patients

✍ Carin E. Dugowson; J. Lee Nelson; Thomas D. Koepsell 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB 👁 3 views

High ten-year risk of cardiovascular dis

High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study

✍ Hilal Maradit Kremers; Cynthia S. Crowson; Terry M. Therneau; Veronique L. Roger 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## Objective To estimate the 10‐year absolute risk of cardiovascular (CV) events in newly diagnosed rheumatoid arthritis (RA) patients and the potential contribution of CV risk factors to absolute risk assessment. ## Methods A population‐based incidence cohort of RA patients (defined